A61K39/464714

COMPOSITIONS COMPRISING CelTOS IMMUNOGENS AND ANTIBODIES AND METHOD OF USE THEREOF

The present disclosure provides immunogenic compositions and methods for vaccination with a CelTOS immunogen. The immunogenic composition comprises Babesia, Theileria or Cytauxzoon CelTOS. The immunogenic composition may also comprise CelTOS with structural changes that affect immune recognition.

CYTOKINE-INDUCED KILLER CELLS
20240156871 · 2024-05-16 ·

The present invention relates to cytokine induced Killer cells (CIKs) for use in the treatment of diseases caused by a Plasmodium infection.

ANTI-PLACENTA-CHONDROITIN-SULFATE CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF

The present invention provides an anti-placenta chondroitin sulfate (pl-CS) chimeric antigen receptor and application thereof. The chimeric antigen receptor mainly comprises anti-pl-CS antigen recognition region, a hinge region, a transmembrane region and intracellular region, wherein the anti-pl-CS antigen recognition region is any one of a plasmodium protein VAR2CSA, a part of peptide segment of plasmodium protein VAR2CSA or a pl-CS antibody; and the part of peptide segment of the plasmodium protein VAR2CSA is a peptide segment with the number of amino acid greater than 500 in the plasmodium protein VAR2CSA.

CROSS-REGULATION OF TYPE I INTERFERON SIGNALING PATHWAYS

Compositions and methods for cross-regulation of type I interferon signaling pathways in pDCs for vaccine development are provided.

A Composition, A Treatment Method and An Application Thereof
20190015458 · 2019-01-17 ·

The present invention relates to the field of treatment of tumor, and especially to a composition comprising a plasmodium, a treatment method and an application thereof. The composition of the present invention has therapeutic effects on colorectal carcinoma, lung carcinoma, breast carcinoma, gastric carcinoma and hepatic carcinoma etc., can inhibit the growth of tumor and prolong the life of the tumor patients, whereas has no therapeutic effect on melanoma and lymphoma; meanwhile, the present invention describes that the long-term plasmodium infection has better therapeutic effect on tumors, and the plasmodium immunotherapy of the present invention does not take the fever time as a course standard when treating tumors, but should be used to extend the duration of plasmodium infection as much as possible until the progression of tumors can be controlled under the premise of protecting the organ functions and life safety of the patients.